Acorda Therapeutics (ACOR +11.2%) rises for a second day after AMPYRA shows promise for post-stroke deficit patients. Heard on the conference call: 1) "What got us here [is] an adherence to analysis in science [and] we're not going to deviate from that" just to get into a Phase III trial. 2) An 18-20% improvement in the timed 25-foot walk speed "correlates very well with various measures of clinically meaningful improvement," but the comparison between the current study and the MS study "is not apples-to-apples."
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Feb 27, 2015)
at Benzinga.com (Feb 12, 2015)
at Benzinga.com (Feb 11, 2015)
at Nasdaq.com (Jan 23, 2015)
at CNBC.com (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs